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ABSTRACT: From trauma wards to chemotherapy, red blood cells are
essential in modern medicine. Current methods to bank red blood cells
typically use glycerol (40 wt %) as a cryoprotective agent. Although highly
effective, the deglycerolization process, post-thaw, is time-consuming and
results in some loss of red blood cells during the washing procedures. Here,
we demonstrate that a polyampholyte, a macromolecular cryoprotectant,
synergistically enhances ovine red blood cell cryopreservation in a mixed
cryoprotectant system. Screening of DMSO and trehalose mixtures identified
optimized conditions, where cytotoxicity was minimized but cryoprotective
benefit maximized. Supplementation with polyampholyte allowed 97% post-
thaw recovery (3% hemolysis), even under extremely challenging slow-freezing and -thawing conditions. Post-thaw washing of the
cryoprotectants was tolerated by the cells, which is crucial for any application, and the optimized mixture could be applied directly to
cells, causing no hemolysis after 1 h of exposure. The procedure was also scaled to use blood bags, showing utility on a scale relevant
for application. Flow cytometry and adenosine triphosphate assays confirmed the integrity of the blood cells post-thaw. Microscopy
confirmed intact red blood cells were recovered but with some shrinkage, suggesting that optimization of post-thaw washing could
further improve this method. These results show that macromolecular cryoprotectants can provide synergistic benefit, alongside
small molecule cryoprotectants, for the storage of essential cell types, as well as potential practical benefits in terms of processing/
handling.
■ INTRODUCTION
Blood banks supply donated blood, primarily consisting of red
blood cells (RBCs), to treat patients for blood loss due to
injury, surgery, or during chemotherapy. However, blood has a
limited refrigerated shelf life and can only be stored for 35
days, according to NHS (UK) guidelines.1 Cryopreserved
blood is just as effective as fresh blood2 and, with
cryopreservation, the storage time of RBCs can be extended
indefinitely,3 allowing the blood to be used in remote areas4,5
and to mitigate supply during times of restricted stocks/
donations or due to disasters.6,7 RBC cryopreservation is also
used in diagnostics8 and for veterinary blood banking, where
blood from a specific species may be difficult to source, making
a blood bank challenging to establish.9−11
In order to freeze cells of any type, cryoprotectants must be
introduced to protect against mechanical ice damage, osmotic
stress, and the dehydration that ice growth causes.12 This must
be balanced against the intrinsic cytotoxicity of the
cryoprotectants, which are typically organic solvents, with
dimethyl sulfoxide (DMSO) widely used for nucleated
cells.13−16 Current cryopreservation practices for RBCs use
20−40 wt % glycerol, which must be added slowly to avoid
osmotic shock and then slowly washed out prior to
transfusion.17,18 Washout is ideally performed using an
automated system,19,20 which slowly reduces the concentration
of glycerol in the solution, allowing glycerol to diffuse out of
the RBCs at a rate that does not cause osmotic stress. This
deglycerolization process takes 30−60 min per unit (475 mL)
of blood,21 meaning that, during an unexpected surge in
demand for blood, such as during a natural disaster or in a
military setting, there could be a significant delay before frozen
blood becomes available.4 Although the use of DMSO to
cryopreserve RBCs has been studied (particularly for nonhu-
man blood),9,22 it is not widely used for RBC cryopreservation,
even though it can be more rapidly washed out (compared to
glycerol) due to its greater membrane permeability and lower
working concentrations.22,23 This may be due to cytotox-
icity24,25 or lack of effectiveness compared to glycerol, but it
has been shown to be potent for animal RBCs.9,22
Trehalose (a nonreducing disaccharide of α-linked glucose)
is produced by extremophiles such as tardigrades26−30 to
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survive in extreme cold environments. Trehalose is noncell
permeable and hence acts in the extracellular space, where it
reduces ice formation by disrupting hydrogen bonding.31,32
Trehalose may aid in stabilizing the membrane33 and can
stabilize proteins.34,35 Trehalose can replace the hydrogen-
bonding function of water during desiccation36 and lyophiliza-
tion35 and is known to be at its most effective when it is
present on both sides of the cell membrane.37 For this reason,
materials and techniques have been developed to deliver
trehalose intracellularly38 and trehalose-side chain polymers
have been reported to protect proteins during lyophiliza-
tion.28,39 Trehalose has been shown to enhance RBC
cryopreservation37 and neutralize cryoprotectant toxicity in
RBCs.40
Another approach evolved by freeze-avoidant extremophiles
is the production of ice-binding proteins41 (also known as
antifreeze proteins). These macromolecules can bind to ice,
acting to promote ice nucleation42 or noncolligatively reduce
the equilibrium freezing point leading to a thermal hysteresis
gap.41,43−45 One particular property of IBPs is ice recrystalliza-
tion inhibition (IRI). Ice recrystallization is a source of
damage, especially during thawing, in cryopreserved samples
and the addition of antifreeze proteins46 (or polymeric/
material mimics)47−51 has been found to improve post-thaw
outcomes by controlling extracellular ice growth.52 Small
molecule IRIs developed by Ben and co-workers have also
been shown to be potent ice growth inhibitors.53 Bromo-
phenyl-β-D-glucopyranoside was shown to enable ∼95% post-
thaw membrane integrity of red blood cells with a reduced
glycerol concentration of 15 wt %.54 However, IRIs alone do
not always give significant improvements in recovery between
different systems and it is clear that all the other mechanisms
of damage during cryopreservation should be addressed.
Matsumura and Hyon. reported that poly(L-lysine)-based
polyampholytes, polymers with mixed positive and negative
charges along the backbone,55 were potent cryopreservation
enhancers, especially when used with, for example, DMSO.
Polyampholytes have weak IRI activity56,57 and appear to aid
cryopreservation during slow freezing by a distinct mechanism,
which could be membrane stabilization.58 There are also
reports of polyampholytes being used to improve vitrification
processes (ice-free cryopreservation achieved using high
solvent concentrations) potentially by inhibiting ice forma-
tion.59 Polyampholytes have been used for stem (stromal)
cell,60 cell monolayer,61 and fibroblast62 cryopreservation. A
key point to note is that polyampholytes, when used as the sole
cryoprotectant, do not always allow successful cryopreserva-
tion. Immediate post-thaw viability values can be false positives
(overestimation of function),63 which is revealed by longer-
term post-thaw culture experiments, and supplemental
cryoprotectants (such as DMSO) may be required.62 This
evidence suggests that polyampholyte-mediated cryopreserva-
tion could be optimized by using it in addition to other
cryoprotectants, which each have distinct modes of action, and,
more specifically, could be applied as alternatives to glycerol
for RBC cryopreservation.
Here, we screened combinations of trehalose (an extrac-
ellular cryoprotectant) and DMSO (an intracellular cryopro-
tectant) with added polyampholytes to find conditions for
ovine RBC cryopreservation. This approach identified a
cryoprotectant formulation resulting in <3% post-thaw
hemolysis, and recovery of intact ovine RBCs that did not
show signs of osmotic stress, and was also shown to work on
large (400 mL) volumes. Flow cytometry, phase contrast and
confocal microscopy, and adenosine triphosphate (ATP)
assays confirmed the cell recovery and demonstrated that
mixed cryoprotectant strategies can be used to improve post-
thaw recoveries.
■ EXPERIMENTAL SECTION
Materials and Methods. DMSO (analytical reagent grade),
poly(methyl vinyl ether-alt-maleic anhydride) (average Mn ≈ 80,000
Da, impurities: <2% benzene), Dulbecco’s phosphate-buffered saline
(1.15 g L−1 dibasic sodium phosphate, 0.2 g L−1 potassium chloride, 8
g L−1 sodium chloride, and 0.2 g L−1 monobasic potassium
phosphate) (DPBS) were purchased from Sigma-Aldrich. Trehalose
dihydrate (purity >98%) was purchased from Carbosynth. Poly-
(ethylene glycol) (PEG) (average Mn = 4000 g mol−1) was purchased
from Sigma-Aldrich. 2-Dimethylaminoethanol (purity 99%) was
purchased from Acros Organics. Tetrahydrofuran (laboratory reagent
grade) was purchased from Merck. BD FACSFlow sheath fluid was
purchased from BD biosciences. Sheep’s blood in Alsever’s solution
(not defibrinated) was from TCS Biosciences. Polyampholyte
(poly(vinyl ether-alt-maleic acid mono(dimethylamino ethyl)ester))
was synthesized in house as described in the Supporting Information
Milli-Q ultrapure water (>18.2 MΩ cm−1 2 ppb) was used
throughout.
Blood Preparation. 10 mL sheep’s blood in Alsever’s solution
was transferred into a centrifuge tube and centrifuged for 5 min at
367g (2000 rpm). The resulting supernatant was discarded and
replaced with 7 mL DPBS and mixed by inversion. The resulting
hematocrit was 30%.
High-Throughput Freezing. A liquid-handling system (Pipet-
max, Gilson) was used to mix 50 μL of two different cryoprotectants
at 2× of final concentration in each well of a 96-well plate. The system
then mixed 100 μL of blood prepared in DPBS with the
cryoprotectants for a final volume of 200 μL per well. RBCs were
incubated with cryoprotectants for 10 min before being frozen in
liquid nitrogen vapor. After 20 min, the plate was removed and
warmed for 5 min in a 37 °C water bath. The positive and negative
controls, DPBS and lysate (100 μL blood, 100 μL lysis buffer,
respectively), were added. The plate was centrifuged at 2250 x g
(3700 rpm) for 5 min and the AHD assay was conducted as described
below. Lysis buffer was 0.32 M sucrose, 5 mM MgCl2, 10 % wt triton
X-100, and 10 mM tris HCl pH 7.8.
Washout. The stock washout solution used was 10% DMSO +
100 mM trehalose in Alsever’s solution. This was replaced with
varying amounts of Alsever’s solution for use in each washout step.
Blood was transferred into Eppendorf tubes and centrifuged at 2000g
(6000 rpm) for 1 min. The pellet was resuspended in prewarmed 37
°C 80% washout solution. This was repeated for 40, 20, and 0%
washout solutions. Finally, intact RBCs were pelleted to collect
remaining lysed blood in the supernatant. The hemolysis from each
step was added to calculate post-freeze−thaw−wash survival.
AHD (Hemolysis) Assays. The alkaline hematin D-575 (AHD)
assay64 was used to assess hemolysis after high-throughput freezing;
the liquid-handling robot transferred 8 μL of the resulting supernatant
from each well to 100 μL AHD solution (100 mL water, 2.5 g triton
X100, 0.5 g NaOH) in a 96-well plate. Each well was then manually
stirred to ensure any remaining precipitate dissolved. Absorbance of
the AHD plate was measured at 580 nm using a plate reader (Synergy
HT, BioTek). Recovery was calculated as: (1-(Absorbance-DPBS/
(lysate-DPBS)) × 100. For vial freezing, 40 mL of the supernatant
from each sample was transferred to 750 mL AHD solution.
Vial Freezing and Large-Volume Assays. For vial freezing, 500
μL blood prepared in DPBS was transferred to Eppendorf tubes and
centrifuged for 5 min at 2000g (6000 rpm). The resulting pellet was
mixed with 1 mL cryoprotectant solution, transferred to cryovials, and
incubated for 10 min. Samples were then plunged into LN2, or
inserted into a cooler (Coolcell LX Corning) and cooled at −1 °C
min−1 to −80 °C for 2 h. Samples were warmed in a 37 °C water bath
for 5 min or at ambient temperatures until thawed. Finally, samples
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were centrifuged at 2000g (6000 rpm) for 5 min. For high-volume
freezing, 200 mL 2× cryoprotectant was mixed with 200 mL blood
and transferred to PVC blood bags (TRO-DONEX, Praxisdienst),
cooled in a −80 °C freezer to −80 °C, and thawed in a 37 °C water
bath. Washing and the AHD assay were carried out as above, using 1
mL aliquots from the bag for the high-volume assay.
Cytotoxicity Assay. 500 μL blood was transferred to centrifuge
tubes and centrifuged at 2000g (6000 rpm) for 5 min. The pellet was
mixed with 1 mL cryoprotectant solution, transferred to cryovials, and
incubated for the desired time. Blood was then centrifuged for at
2000g (6000 rpm) for 5 min. The AHD assay was carried out as
above.
Confocal Microscopy. Live red blood cell confocal imaging,
before and after freezing with cryoprotectants, was undertaken using a
Zeiss LSM 710 inverted microscope, equipped with three photo-
multiplier detectors (GaAsP, multialkali, and BiG.2) and a multi-
channel spectral imaging detector. Red blood cells (diluted 500-fold)
were placed on MatTek glass bottom dishes (no. 1.5, 35 mm) and
brightfield images were taken using a C-Apochromat 63x/1.20 W
Korr M27 objective lens and ×3.0 zoom. Z-stacks were taken every z
= 0.3 μm until the whole cell was imaged. Zeiss ZEN (black edition)
2.3 lite was utilized for image collection and maximum intensity
projection processing.
ATP Luciferase Assay. 5 μL of the recovered blood (not
normalized to cell count or recovery, using the cryopreservation/
washing procedure described above) was added to 95 μL Alsever’s
solution in a 96-well plate. 100 μL CellTiter-Glo 3D Reagent
(Promega) was added, and the solution was thoroughly mixed, then
incubated at ambient temperatures for 30 min. Luminescence (visible
light ∼740 to 380 nm) was then measured using a plate reader
(Synergy HT, BioTek). Background noise was controlled by
subtracting luminescence from samples that were incubated with
Alsever’s solution instead of the CellTiter-Glo 3D Reagent. To make
the standard curve, 0.011 g adenosine 5′-triphosphate disodium salt
hydrate (Thermo Scientific) was added to 1 L of distilled water and
diluted via serial dilatation in a 96-well plate. The luciferase assay was
conducted as above. The initial 20× dilution of the original samples
was accounted for when calculating the final ATP concentration.
■ RESULTS AND DISCUSSION
The core hypothesis for this work was that the cytotoxicity
associated with many cryoprotectants could be mitigated by
combining multiple cryoprotectants (small molecule and
macromolecular) at concentrations lower than they would
normally be used individually. As each cryoprotectant has a
unique mechanism of action (or toxicity), a synergistic
cryoprotectant outcome could potentially be achieved. This
approach would allow additional benefits from polyampholytes
(a versatile and diverse class of macromolecular cryoprotec-
tants)55,65 to be realized. This is crucial as, at present,
polyampholytes function as supplemental, rather than as the
sole, components.62 Our polyampholyte of choice, poly(vinyl
ether-alt-maleic acid mono(dimethylamino ethyl)ester), was
synthesized from commercially available poly(methyl vinyl
ether-alt-maleic anhydride) undergoing a single-step ring-
opening reaction with 2-dimethylaminoethanol.61 This syn-
thetic route is scalable and can be conducted using high-grade
materials, and hence is suitable for scale-up and translation. As
glycerol is challenging to remove from RBCs post-thaw and has
already been widely investigated,66 DMSO and trehalose were
chosen as alternative cryoprotectants. These are not normally
used for blood as DMSO is hemolytic at the high
concentration, where it can be used as the lone cryoprotectant
Figure 1. Cryopreservation screening using mixtures of trehalose and DMSO. Chemical structures of (A) trehalose; (B) polyampholyte (poly(vinyl
ether-alt-maleic acid mono(dimethylamino ethyl)ester)); (C) PEG Mn = 4000 g mol−1; (D) DMSO; and (E) heat map showing RBC recovery
using different cryoprotectant mixtures. DMSO concentrations are on the x-axis (Dx v/v %) and increasing trehalose concentrations down the y-
axis (Tx mmol). Total volume of 200 μL in each well (100 μL of ovine RBCs suspended in DPBS). Solutions were frozen in liquid nitrogen vapor
and thawed in a 37 °C water bath. Hemolysis was assessed using the AHD assay and recovery is reported as 100%hemolysis.
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for RBCs, and trehalose is noncell penetrative and hence has
limited benefits on its own. Therefore, combining these three
very different cryoprotectants may allow for high recoveries in
a nontraditional RBC cryopreservation formulation. Using a
robotic liquid-handling system, combinations of DMSO (0−
8% v/v) and trehalose (0−300 mM) were prepared, applied to
ovine red blood cells (a model for human RBCs)67 and
screened for cryopreservation in 96-well plates. It should be
noted that the 96-well plates (unless using a specialized
freezer)68 are not optimal conditions for freezing RBCs (in
terms of total recovery) but allow rapid screening to find
candidate solutions for further testing.69 Cryopreservation
success was determined by the alkaline hematin D-575 (AHD)
assay, in which hemoglobin is converted to AHD and the
concentration is determined relative to a control using UV−Vis
spectroscopy at 575 nm.64 In total, 54 conditions were
screened and the results of this are shown in the heat map in
Figure 1 (data are also tabulated in Figure S2). Note that the
concentrations indicated are the units most commonly used for
those cryoprotectants, to allow comparison with the diverse
literature that do not use identical units: solvents such as
DMSO are denoted using percentage by volume, osmolytes
(trehalose) using molarity, and polymers by weight per mL.
Unless otherwise stated, all cryoprotectants were dissolved in
DPBS (8 g L−1 sodium chloride, 0.2 g L−1 potassium chloride,
0.2 g L−1 monobasic potassium phosphate, and 1.15 g L−1
dibasic sodium phosphate). Trehalose alone gave a maximum
recovery of 39% at 300 mM. DMSO at 8% v/v (the highest
concentration in the screen, due to dilution factors within the
mixing protocol) gave an average (mean) recovery of 63%,
which increased to 70% when combined with 300 mM
trehalose. While 70% recovery for a nucleated cell line would
be a significant post-thaw result, for RBCs glycerol can give
>85% recovery post-thaw.19 This highlights the challenge of
discovering innovative solutions, which can reach the high level
of protection offered by glycerol, while being comparatively
easy to washout. As a control, betaine was explored by this
matrix strategy with trehalose, but there was no evidence of
synergy, which is potentially due to their likely similar
mechanisms of action (Supporting Information).
Encouraged by the screening results, vial-based freezing (to
ensure consistent cooling rates for each sample) was
undertaken. The data in Figure 1 showed that trehalose had
less impact at higher DMSO concentrations than at lower
concentrations. Similarly, the overall difference in recovery
between 100 mM trehalose and higher concentrations (300
mM) was minimal, hence 100 mM was chosen to ensure the
total osmotic pressure (explored later) was not too high.
Cryopreservation was evaluated under fast freeze/fast thaw
conditions (frozen in liquid nitrogen and thawed in a 37 °C
water bath) and the results are shown in Figure 2. As might be
expected for these conditions, the trehalose and polyampholyte
alone gave moderate recoveries (∼40%). The polyampholyte
has been reported (as the sole cryoprotectant) to give above
50% recovery in RBCs61 but, as can be seen here, the recovery
varied between samples when used as a sole cryoprotectant.
However, previous reports used PBS, not DPBS, as the carrier
(which has additional ions), which may explain this variance.
When the polyampholyte was combined with DMSO, the post-
thaw recovery was increased to 98%. Without the trehalose,
recovery was slightly lower, with a larger spread of results,
suggesting that the mixed cryoprotectant strategy helps
mitigate different modes of damage, leading to an exceptional
recovery with almost no batch-to-batch variance. This supports
our hypothesis that the combination of extracellular
(trehalose) and intracellular (DMSO) cryoprotectants, at
lower concentrations than conventionally used (to reduce
hemolysis), provides a synergistic benefit. Furthermore, the
polyampholyte helps mitigate damage further, which is
explored more below.
To test the system further, a more challenging slow-thaw
approach (which enables recrystallization to occur, causing
significant damage)48,54 was employed. The results were in
agreement with the fast thaw data from Figure 2, with the
mixed cryoprotectant solution again leading to < 2% hemolysis
(Figure 3). This polyampholyte is not a potent IRI, but at the
concentration applied here it can inhibit ice growth, which may
be mitigating some of the damage56,61 (although any
macromolecule at sufficiently high concentration can slow ice
growth). However, the extent of cell recovery here is greater
than using poly(vinyl alcohol), which is a potent IRI,48 and
hence the primary mode of action of the polyampholyte would
seem to be distinct.
The addition of 100 mg mL−1 PEG was explored as an
additional additive for this process. The rationale was that
many uncharged water-binding macromolecules can benefit
RBC cryopreservation to an extent, as exemplified by
poly(hydroxyethyl starch).70 PEG has proven to be effective
in other cell types71 and, when used in combination with
polymeric IRIs, for protein/bacteria storage.72,73 Addition of
PEG was not detrimental to cryopreservation and may have
Figure 2. Recovery of RBCs after being rapidly frozen in liquid
nitrogen and thawed for 5 min in a 37 °C water bath. Prior to
freezing, RBCs were incubated for 10 min with the cryoprotectant. Pa
= 100 mg mL−1 polyampholyte, D = 10% DMSO, and T = 100 mM
trehalose. Data represent the mean ± SD of at least three independent
experiments (N = 19, P = 0.0008, and *P < 0.05 from 10% DMSO).
Figure 3. Recovery of RBCs after being rapidly frozen in liquid
nitrogen and thawed in air at ambient temperatures. Prior to freezing,
RBCs were incubated for 10 min with the cryoprotectants. Pa = 100
mg mL−1 polyampholyte, D = 10% DMSO, T = 100 mM trehalose,
and P = 100 mg mL−1 PEG. Data represent the mean ± SD of at least
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yielded a small (but statistically insignificant) improvement.
However, additional benefits of using PEG were realized when
variable freeze/thaw rates were tested (see below).
These results are important, as they show that minimal
hemolysis occurs in these mixed cryoprotectant solutions and
that the formulation is tolerant to changes in freezing/thawing
rates, which are challenging to control with precision in larger
volume samples (addressed later in the article). To explore
conditions that might be considered least optimal (slow freeze
+ slow thaw), but the most practical for red blood cell storage,
a panel of cryoprotectant formulations were further tested
(Figure 4). Under these conditions, the weak IRI activity of the
polyampholyte will provide some benefit by reducing ice
growth in slow thawing, even though this property does not
appear to be its primary mode of cryoprotection.65 It was also
important, from a practical perspective, to explore the use of
water rather than DPBS as the carrier solution for the
cryoprotectants. The rationale behind this was that the use of
high molar concentrations of extracellular cryoprotectants will
increase the osmolarity of the solutions beyond optimal
physiological levels. Therefore, by removing the noncryopro-
tective ions found in DPBS, the osmolarity of the solution can
be reduced to be closer to the optimal level. We found that
when blood was cryopreserved with 300 mM trehalose in H2O,
the resulting recovery was higher than blood cryopreserved in
300 mM trehalose in DPBS (Supporting Information). The
measured osmolarity of 100 mg mL−1 polyampholyte + 100
mM trehalose in DPBS was 563 mOsm, whereas 100 mg mL−1
polyampholyte + 100 mM trehalose in H2O has a combined
osmolarity of 239−276 mOsm. This is closer to the
physiological osmolarity of blood, which is around 288
mOsm.74 These measurements exclude DMSO because
DMSO enters the cell and equilibrates, canceling out its effect
on osmotic stress once equilibrium is reached. The panel was
designed to highlight the importance of each individual
component and to determine how essential each component
is. To ensure any reduction in cell recovery post-thaw was not
due to intrinsic toxicity (i.e., lysis), all solutions were first
incubated with red blood cells for 1 h and hemolysis was
determined, shown in Figure 4A. The only condition that
showed appreciable hemolysis was 10% DMSO + 100 mg
mL−1 polyampholyte. However, the addition of trehalose and/
or PEG to the cryoprotectant solution reduced hemolysis to
negligible levels, suggesting that they neutralize the combined
toxicity of DMSO and polyampholyte. In the case of trehalose,
its ability to neutralize cryoprotectant toxicity has been
previously reported.36 PEG has the ability to stabilize proteins,
which might be beneficial here,75 but it also replaces water and
hence reduces the total ice fraction formed. Ultimately, these
hemolysis data show that any reduction in recovery during the
process of cryopreservation can, therefore, be attributed to
freeze-induced damage, not cytotoxicity.
Figure 4B shows the results of cryopreservation screening
using the above formulations. The results after cooling blood at
a rate of −1 °C min−1 and slowly warming at ambient
temperature, until thawed, demonstrate that the most effective
formulation was PaDT-H2O (100 mg mL
−1 polyampholyte,
10% DMSO, and 100 mM trehalose, in water), giving a post-
thaw recovery of 97% (Figure 4B). DMSO was essential in
these, highlighting the need for an intracellular cryoprotectant.
The addition of trehalose and/or polyampholyte was able to
enhance the cryoprotective effect of DMSO to enable near-
zero hemolysis.
Our approach of using increasingly challenging freeze/thaw
rates is supported by the reduction in the effectiveness of 10%
DMSO when used alone, across all three freezing experiments,
from 81% (fast freeze/thaw) to just 54% when slow freeze/
thaw was used. By only using optimized conditions, which
cannot be replicated with clinically relevant volumes of blood,
overestimation of recovery is possible. Our unique polymer-
containing formulations clearly mitigate these problems. The
formulation giving the highest recovery, PaDT-H2O, was
singled out for further testing; PaDT-H2O was not hemolytic
at the 1 h time point and did not show any progressive
hemolysis when measured at the 15, 30, 45, and 60 min time
points (Supporting Information).
Before cryopreserved blood can be used in a medical or
research scenario, the cryoprotectants are ideally washed out.
To ensure that it was possible to remove the cryoprotectants
post-thaw, RBCs cryopreserved with PaDT-H2O were pelleted
and resuspended in 80% washout solution (stock washout
solution is 10% DMSO + 100 mM trehalose in Alsever’s
solution). This was repeated for 40% then 20% washout
solutions before being resuspended in Alsever’s solution. The
washout process was achieved in under 10 min. The final post-
freeze−thaw−wash recovery was 80% (Figure 5). Although
this was not a statistically significant difference from the 97%
recovery obtained immediately post-thaw, this does represent a
small loss during washout. Hemolysis during washout could be
Figure 4. Vial-based cryopreservation of cryoprotectant formulations.
(A) Recovery of RBCs after being incubated with cryoprotectants for
1 h. Data represent the mean ± SD of three independent experiments
(N = 51, P = 0.1582, and *P < 0.05 from 10% DMSO). (B) Recovery
of RBCs after being cooled at −1 °C min−1 to −80 °C and thawed in
air at ambient temperatures. Prior to freezing, RBCs were incubated
for 10 min with the cryoprotectants. Data represent the mean ± SD of
at least three independent experiments (N = 19, P = 0.0008, and *P <
0.05 from 10% DMSO). Pa = 100 mg mL−1 polyampholyte, D = 10%
DMSO, T = 100 mM trehalose, and P = 100 mg mL−1 PEG.
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further reduced by using a cell-processing device.17,19 For
comparison, Briard et al. reported up to 80% recovery when
using small molecule ice recrystallization inhibitors in
cryopreservation mixtures containing 15 wt % glycerol, but
these were prewashout values.76 Hence, our macromolecular
approach can match, or even outperform, current methods and
may allow for faster washing-out processes, which would need
to be validated in automated systems in the future.
To assess the post-freeze−thaw−wash integrity, flow
cytometry was used to assess the RBC morphology (Figure
6A−D). RBCs were cryopreserved in the optimal PaDT-H2O
formulation under slow-freeze/slow-thaw conditions and
washed using the method described above. Size (forward
scatter) would be increased in swollen RBCs, whereas optical
complexity (side scatter) would be increased in crenated
(shrunken) cells. These analyses would indicate if cells are
damaged in such a way as to alter the shape of their surface
membrane, have internal damage resulting in granule/inclusion
body formation, or blebbing that indicates apoptosis or
cytoskeletal damage.77,78 Compared to fresh RBCs (Figure
6A), those cryopreserved in our formulation (after washout)
showed similar profiles (Figure 4B). For comparison, RBCs
were also suspended in hypotonic (0.125 M) and hypertonic
(0.5 M) saline solutions showing how forward/side scatter
profiles would change in response to osmotic stress. The
RBC’s morphology was also investigated by optical microscopy
(Figure 6E−G), ruling out any crenation due to osmotic stress,
and hence our solutions clearly lead to intact RBCs post-thaw.
Osmotic fragility assays (Figure S5) also suggest the RBCs are
intact post-thaw and washout.
To further investigate the post-thaw integrity of the RBCs,
live confocal microscopy was used (Figure 7A). Cells were
cryopreserved in PaDT-H2O, thawed, and washed as described
above and compared to nonfrozen controls. Compared to the
control, a higher proportion of the cells appears to be crenated,
which may reflect the minor differences observed in the
forward and side scatter shown by flow cytometry (Figure 6).
The shrinkage suggests that the exact osmolarity of the
washout solutions could be tuned further and that replacement
of some salts into the cryopreservation buffer (which to control
osmolarity used water not saline) may provide opportunity to
optimize this. To investigate the function of the cells, ATP
levels post-thaw were compared. ATP depletion results in a
reduction of the cell’s ability to maintain homeostatic processes
such as ion transport maintenance of the cytoskeleton and
membrane, which could lead to crenation.79,80 A fluorescence-
based luciferase assay: CellTiter-Glo 3D Cell Viability Assay
(Promega), was used to measure the concentration of ATP.
RBCs were cryopreserved in PaDT-H2O or 10 wt % DMSO,
thawed, and washed as described above. The RBCs were
stored for 24 h at 4 °C prior to the assay to allow any delayed
leakage to be observed. The ATP concentration in post-
freeze−thaw−wash RBCs frozen with PaDT-H2O was similar
to that of the fresh control (3.1 vs 3.7 μM). Both were
significantly higher than cells cryopreserved with DMSO-alone.
ATP loss in cells (Figure 7B) cryopreserved with PaDT-H2O
does not exceed average hemolysis, (20% hemolysis vs 16%
loss of ATP), therefore the loss of ATP is likely due to cell loss
during cryopreservation and washout, rather than indicating a
loss of viability. This is in agreement with previous research,
which shows that cryopreservation of RBCs does not result in
significant depletion of ATP81 and indicates good metabolic
health.
To test our cryoprotectant solution under more relevant
conditions, a larger volume of RBCs (400 mL) was incubated
with PaDT-H2O for 10 min and frozen in poly(vinyl chloride)
blood bags. This is essential, as thermal gradients upon both
freezing and thawing are minimized in small-volume experi-
ments, such as above, but RBCs are required in larger volumes
for medical settings and hence is a robust challenge. The blood
bags were cooled at an uncontrolled rate by being placed
directly in a −80 °C freezer before thawing in a 37 °C water
bath. Post-thaw recovery was 84.5%, and there was very little
hemolysis during washout (using 1 mL aliquots, not the whole
sample) with a post-freeze−wash−thaw recovery of 83.4%
(Figure 8). This recovery value is higher than the 80%
minimum standard according to the American Association of
Blood Banks82 and U.S. military.83 The slightly lower post-
thaw recovery obtained with large volumes, compared to vials,
is to be expected due to thermal gradients (outside thawing
fast than inside), which may promote ice recrystallization. The
process used here was not optimized and could be enhanced
through more control of freezing/thawing rates or the use of
heat transfer devices to improve contact. However, the high
postwashout recoveries are already in the range for application
and the present method is easy, based on simply placing in a
freezer and thawing in a water bath, which is an appealing
process.
The above data demonstrate the benefit of mixed macro-
molecular cryoprotectant solutions. The mode of action of
polyampholytes is still under investigation,65 but it appears
they do not have a significant impact on the formation/growth
of ice. To ensure that the cryopreservation process used here
was not leading to vitrification (ice-free state), solutions were
analyzed using differential scanning calorimetry (DSC). Latent
heat of cooling during the phase change from liquid water to
ice corresponds to the amount of ice formed. Figure 9 shows
that in each formulation, ice was indeed forming, ruling out
vitrification. The total ice fraction was reduced upon addition
Figure 5. Recovery of RBCs after washing-out cryoprotectant
solutions. RBCs were cooled at −1 °C min−1 to −80 °C and slowly
thawed in air at ambient temperatures. Prior to freezing, RBCs were
incubated for 10 min with the cryoprotectants (10% DMSO, 100 mM
trehalose, and 100 mg mL−1 polyampholyte in water). Prewashout
indicates immediate post-thaw recovery and postwashout indicates
recovery after cryoprotectant removal and reconstitution in Alsever’s
solution. Recovery is 100%hemolysis. Data represent the mean ±
SD of at least three independent experiments. (N = 17, P < 0.0001, *P
< 0.05, ns = not significant).
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of each additive, as would be expected. The top performing
conditions, which also had the largest overall additive
concentration, had the lowest ice fraction. Both the
polyampholyte and trehalose have (relatively weak) ice
recrystallization inhibition activity29,65 but are not reported
to impact ice nucleation (or inhibition of nucleation). The
ability to reduce ice crystal size during freezing has been
proposed as a mechanism of action of DMSO.84
■ CONCLUSIONS
Synergy in mixed cryoprotectant formulations may overcome
the intrinsic toxicity limits associated with high concentrations
of any individual cryoprotectant and take advantage of their
multiple mechanisms of action. Here, the impact of mixing
trehalose, DMSO, and a polyampholyte, which all have distinct
modes of cryoprotective function, was evaluated for red blood
cell cryopreservation. The cryoprotectants were first screened
using liquid-handling systems to identify optimal mixtures in a
96-well plate format. A synergistic effect was identified and
then studied further using vial-based freezing. It was found that
all three components were essential to achieve the best
cryopreservation results, enabling 97% recovery, even with
nonoptimal slow-thawing conditions. The formulation was
nonhemolytic after a 1 h exposure. A particular benefit of this
system was the fast washout of cryoprotectants, which did not
lead to significant cell loss, with 80% of RBCs recovered intact
after washing. This was crucial as deglycerolization of RBCs
can be a time-consuming process, even with automated
Figure 6. Top: Flow cytometry plots showing forward scatter and side scatter of (A) fresh and (B) post-freeze−thaw−wash RBCs in Alsever’s
solution. For comparison are fresh RBCs under (C) hypotonic and (D) hypertonic conditions. Bottom: Phase contrast microscopy images of
RBCs. (E) Fresh in Alsever’s solution. (F) Fresh in DPBS. (G) Post-freeze−thaw−wash in Alsever’s solution. Scale bar represents 20 μm.
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facilities, and simplifying the process without stressing the cells
is crucial for any innovative formulation. A large volume (400
mL) study was conductedthis was essential as vial-based
freezing does not replicate the thermal gradients that blood
bags are exposed to during freezing and thawing. The
cryoprotectant formulation performed well, allowing 84%
postwashout recovery. Flow cytometry and optical microscopy
confirmed that the blood cells were intact, and a luciferase
assay showed that there was no significant loss of ATP
indicative of successful recovery. However, confocal micros-
copy did reveal some morphological changes and shrinkage,
which suggests that optimization of the washout solution and
the ion-balance could further improve this cryoprotectant
formulation, which was formulated in water, not saline, to
control the osmolarity. The exact cryoprotective mechanism of
polyampholytes is not yet clear, but this mixed formulation
benefits from intracellular (DMSO) and extracellular (treha-
lose) protection, which along with the polymer lead to reduced
hemolysis. While these cryoprotectants are not currently used
for blood banking, the results clearly show that combining
cryoprotectants with different modes of action can lead to high
post-thaw recovery, comparable to glycerolization, with the
macromolecular cryoprotectant acting synergistically with the
small molecules. The fast and easy washout procedures may
also find use in reducing the time from thaw to application.
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